新潟医療福祉大学医療経済・QOL研究センター

Site Map　〉

研究実績

2023年

  • Noto S, Murata T, Saito S, Watanabe T, Kobayashi M. Preferences for Rehabilitation in Persons with a History of Stroke: A Discrete Choice Experiment. Patient Preference and Adherence. 2023;17:1611-1620.

  • Noto S. Perspectives on Aging and Quality of Life. Healthcare. 2023;11(15):2131.
  • Kanegane H, Ishimura M, Kawai T, Okada S, Okamatsu N, Go M, Noto S. Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study. Frontiers in Immunology. 2023;14:1244250.
  • Koto Y, Narita A, Noto S, Okada M, Ono M, Baba T, Sagara R, Sakai N. Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study. Molecular Genetics and Metabolism Reports. 2023;36:100994.
  • Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Gradient Boosted Tree Approaches for Mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Onto 5-Level Version of EQ-5D Index for Patients With Cancer. Value Health. 2023 Feb;26(2):269-279.
  • Izumi S, Hagiwara Y, Matsuyama Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L. Health Qual Life Outcomes. 2023 Jan 17;21(1):3.
  • 白岩健，能登真一，小林慎，福田敬．CHEERS（Consolidated Health Economic Evaluation Reporting Standards）2022 詳細と解説―ISPOR（国際医薬経済・アウトカム研究学会）CHEERS II Good Practices タスクフォース報告書―．保健医療科学．2023; 72(4):344-369.
  • Amaki M, Moriwaki K, Nakai M, Yamano T, Okada A, Kanzaki H, Izumo M, Usuku H, Onishi T, Nagai T, Miyamoto Y, Fujita T, Kawai H, Akashi Y, Tsujita K, Matoba S, Kobayashi J, Izumi C, Anzai T. Cost-effective analysis of transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis: A prospective multicenter study. J Cardiol. 2024 Mar;83(3):169-176. doi: 10.1016/j.jjcc.2023.07.018. Epub 2023 Aug 3. PMID: 37543193.
  • Morimoto K, Moriwaki K, Shimozuma K, Nakayama T. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan. J Gastroenterol. 2023 Dec;58(12):1188-1197. doi: 10.1007/s00535-023-02041-3. Epub 2023 Sep 19. PMID: 37725256.
  • 泉 良太，佐野哲也．回復期リハビリテーション病棟脳卒中患者におけるEQ-5D-5Lの測定特性の検討－臨床的に意義のある最小変化量（MCID）について－．総合リハ．2023；51（8），881-884．
  • 青柳翔太，泉 良太．回復期リハビリテーション病棟における認知機能障害者のQOLに対するADL，作業適応，性格特性の影響－構造方程式モデリングを用いた検討－．作業療法．2023；42（3），319-327．
  • Izumi R, Sano T, Hirofumi N, Noto S. Elucidation of changes in health-related QOL and the MCID in cardiovascular diseases -Pilot study-. International society of quality of life research 30th annual conference. Calgary, Canada. 2023.10.18-21.
  • Sano T, Izumi R, Ayumi T. Factors that Improve Health-Related QOL at 3 Months after Discharge from a Recovery-Phase Rehabilitation Ward. International society of quality of life research 30th annual conference. Calgary, Canada. 2023.10.18-21.

2022年

  • Noto S, Wake M, Mishiro I, Hammer-Helmich L, Ren H, Moriguchi Y, Fujikawa K, Fernandez J. Health-Related Quality of Life Over 6 Months in Patients With Major Depressive Disorder Who Started Antidepressant Monotherapy. Value Health Reg Issues. 2022; 30:127-133.
  • Watanabe T, Noto S, Natsumeda M, Kimura S, Tabata S, Ikarashi F, Takano M, Tsukamoto Y, Oishi M. Characteristics of health-related quality of life and related factors in patients with brain tumors treated with rehabilitation therapy. J Patient Rep Outcomes. 2022 Sep 6;6(1):94.
  • Koto Y, Narita A, Noto S, Ono M, Hamada AL, Sakai N. Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan. Orphanet J Rare Dis. 2022 Jul 19;17(1):280.
  • Ito T, Kamei K, Yuasa A, Matsumoto F, Hoshi Y, Okada M, Noto S. Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons. J Dermatol. 2022; 49(6):584-593.
  • Ishihara K, Izawa KP, Noto S, Shimizu I. Changes in Physical and Mental Functions in Patients with Cardiovascular Disease During the First Two Waves of COVID-19 in Japan.　Rev Recent Clin Trials. 2022;17(1):15-19.
  • Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail? Med Decis Making. 2022 Jan;42(1):60-67.
  • Mo X, Moriwaki K, Morimoto K, Shimozuma K. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan. Clin Drug Investig. 2022 Jul;42(7):599-609. doi: 10.1007/s40261-022-01168-0. Epub 2022 Jun 8. PMID: 35675029.
  • Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142. PMID: 35277957.
  • Haryono A, Ikeda K, Nugroho DB, Ogata T, Tsuji Y, Matoba S, Moriwaki K, Kitagawa H, Igarashi M, Hirata KI, Emoto N. ChGn-2 Plays a Cardioprotective Role in Heart Failure Caused by Acute Pressure Overload. J Am Heart Assoc. 2022 Apr 5;11(7):e023401. doi: 10.1161/JAHA.121.023401. Epub 2022 Mar 24. PMID: 35322673; PMCID: PMC9075488.
  • Hoshino E, Konomura K, Obatake M, Moriwaki K, Sakai M, Urayama KY, Shimozuma K. Direct health care cost of treatment and medication of biliary atresia patients using the National Database of Health Insurance Claims and Specific Health Checkups. Pediatr Surg Int. 2022 Apr;38(4):547-554. doi: 10.1007/s00383-022-05079-1. Epub 2022 Feb 15. PMID: 35165784; PMCID: PMC8913443.
  • Hoshino E, Moriwaki K, Morimoto K, Sakai K, Shimohata N, Konomura K, Urayama KY, Suzuki M, Shimozuma K. Cost-Effectiveness Analysis of Universal Screening for Biliary Atresia in Japan. J Pediatr. 2023 Feb;253:101-106.e2. doi: 10.1016/j.jpeds.2022.09.028. Epub 2022 Sep 27. PMID: 36179888.
  • 佐野哲也，泉 良太，佐野真裕子．医療療養型病床の特徴と健康関連 QOL との関係－単施設における予備的研究－．リハビリテーション科学ジャーナル2022；18：31-38．
  • Izumi R, Sano T, Hirofumi N, Noto S, Yukako Y, Takizawa H. Elucidation of changes in health-related QOL and the MCID in motor disorders. International society of quality of life research 29th annual conference. Prague, Czech Republic. 2022.10.19-22.

2021年

  • Noto S, Miyazaki M, Takeuchi H, Saito S. Relationship between hemodialysis and health-related quality of life: a cross-sectional study of diagnosis and duration of hemodialysis. Renal Replacement Therapy. 2021; 7, Article number: 62.
  • Obata H, Izumi T, Yamashita M, Mitsuma W, Suzuki K, Noto S, Morimoto T, Isobe M. Characteristics of Elderly Patients with Heart Failure and Impact on Activities of Daily Living: A Registry Report from Super-Aged Society. J Card Fail. 2021 Nov;27(11):1203-1213.
  • Iwatani T, Noto S, Tsugawa K. Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer. Curr Oncol. 2021 Oct 18;28(5):4203-4212.
  • Noto S, Saito S, Shiroiwa T, Fukuda T. Estimation of Lifetime QALYs Based on Lifestyle Behaviors. Int J Environ Res Public Health. 2021 Sep 22;18(19):9970.
  • Shiroiwa T, Noto S, Fukuda T. Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings. Value Health. 2021 Aug;24(8):1193-1202.
  • Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021 Jul;41(5):597-606.
  • Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J. Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J. Neuropsychiatr Dis Treat. 2021 Mar 26;17:945-955.
  • Saito S, Qi R, Tran HTT, Suzuki K, Takiguchi T, Noto S, Ohde S, Takahashi O. A nationwide web-based survey of factors associated with depressive symptoms among Japanese workers. Int J Soc Psychiatry. 2021 May 13:207640211017586.
  • Saito S, Tran HTT, Qi R, Suzuki K, Takiguchi T, Ishigami K, Noto S, Ohde S, Takahashi O. Psychological impact of the state of emergency over COVID-19 for non-permanent workers: a Nationwide follow-up study in Japan. BMC Public Health. 2021 Feb 11;21(1):334.
  • Ishihara K, Izawa KP, Noto S, Shimizu I. Physical and Mental Functions of Cardiovascular Diseased Patients Decrease During the State of Emergency Initiated by the COVID-19 Pandemic in Japan. Rev Recent Clin Trials. 2021;16(3):316-321.
  • Morimoto K, Moriwaki K, Kaneyasu T, Nakayama H, Shimozuma K. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan. Value Health Reg Issues. 2022 Mar;28:54-60. doi: 10.1016/j.vhri.2021.04.003. Epub 2021 Nov 17. PMID: 34800832.
  • Mizumoto M, Fuji H, Miyachi M, Soejima T, Yamamoto T, Aibe N, Demizu Y, Iwata H, Hashimoto T, Motegi A, Kawamura A, Terashima K, Fukushima T, Nakao T, Takada A, Sumi M, Oshima J, Moriwaki K, Nozaki M, Ishida Y, Kosaka Y, Ae K, Hosono A, Harada H, Ogo E, Akimoto T, Saito T, Fukushima H, Suzuki R, Takahashi M, Matsuo T, Matsumura A, Masaki H, Hosoi H, Shigematsu N, Sakurai H. Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines. Cancer Treat Rev. 2021 Jul;98:102209. doi: 10.1016/j.ctrv.2021.102209. Epub 2021 Apr 16. PMID: 33984606.
  • Ohde S, Moriwaki K, Takahashi O. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification. BMC Endocr Disord. 2021 May 22;21(1):105. doi: 10.1186/s12902-021-00771-0. PMID: 34022872; PMCID: PMC8141129.
  • 泉良太，能登真一，佐野哲也，鈴木達也．回復期リハビリテーション病棟における健康関連QOLの変化と代理人回答の一致度について-脳卒中患者へのEQ-5D-5Lによる評価-．日本臨床作業療法研究2021；8：31-36．

2020年

  • Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Health Qual Life Outcomes. 2020 Nov 3;18(1):354. doi: 10.1186/s12955-020-01611-w.
  • Noto S, Takahashi O, Kimura T, Moriwaki K, Masuda K. The relationship between preference-based health-related quality of life and lifestyle behavior: a cross-sectional study on a community sample of adults who had undergone a health check-up. Health Qual Life Outcomes. 2020 Aug 3;18(1):267. doi: 10.1186/s12955-020-01518-6.
  • Noto S, Shiroiwa T, Kobayashi M, Murata T, Ikeda S, Fukuda T. Development of a multiplicative, multi-attribute utility function and eight single-attribute utility functions for the Health Utilities Index Mark 3 in Japan. J Patient Rep Outcomes. 2020 Apr 3;4(1):23. doi: 10.1186/s41687-020-00188-8.
  • Fukuda H, Yano Y, Sato D, Ohde S, Noto S, Watanabe R, Takahashi O. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan. Pharmacoeconomics. 2020 Mar;38(3):297-306. doi: 10.1007/s40273-019-00861-x.
  • Noto S, Uemura T. Japanese health utilities index mark 3 (HUI3): measurement properties in a community sample. J Patient Rep Outcomes. 2020 Jan 29;4(1):9. doi: 10.1186/s41687-020-0175-5.
  • Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Wakumoto Y, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Funagoshi M, Arakawa I, Noto S, Shimozuma K. Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems". Qual Life Res. 2020 Mar;29(3):755-763. doi: 10.1007/s11136-019-02316-4.
  • Tran HTT, Saito S, Noto S, Suzuki K. Quality of Life and Eligibility for Specific Financial Assistance for Medical Expenses: A Cross-Sectional Web-Based Survey among Patients with Inflammatory Bowel Disease in Japan. Gastrointest. Disord. 2020, 2, 12. http://dx.doi.org/10.3390/gidisord2020012
  • Noto S, Shiroiwa T, Kobayashi M, Murata T, Izumi R, Fukuda T. Construct validity of a new Japanese multiplicative, multi-attribute utility function and eight single-attribute utility functions for the Health Utilities Index Mark 3. ISOQOL 27th Annual Conference (Virtual Event). 19 – 23 October 2020.
  • Moriwaki K, Uechi S, Fujiwara T, Hagino Y, Shimozuma K. Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. PharmacoEconomics Open. 2021 https://doi.org/10.1007/s41669-020-00254-3
  • Kinoshita T, Moriwaki K, Hanaki N, Kitamura T, Yamakawa K, Fukuda T, Hunink MGM, Fujimi S. Cost-effectiveness of a hybrid emergency room system for severe trauma: a health technology assessment from the perspective of the third-party payer in Japan. World J Emerg Surg 16, 2 (2021). https://doi.org/10.1186/s13017-020-00344-x
  • Hashimoto M, Aogaki K, Numata C, Moriwaki K, Matsuda Y, Ishii R, Tanaka I, Okamoto Y. Factors influencing the prescribed dose of opioid analgesics in cancer patients. J Opioid Manag. 2020 Jul/Aug;16(4):247-252.
  • Fukuda H, Sato D, Moriwaki K, Ishida H. Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma. PLoS One. 2020 Aug 13;15(8):e0237316.

2019年

  • 田村和子，佐藤卓也，能登真一，今村徹．軽度から中等度のアルツハイマー病患者における健康関連 QOL の検討　新しい尺度である５水準版の EQ-5D を用いて．BRAIN and NERVE．2019；71：67-73．
  • 森脇 健介. 医療技術の費用対効果評価ー基本手法と事例ー. 日本整形外科学会雑誌93 606-613. 2019
  • 泉良太（分担）．セラピストのための脳卒中評価指標の解釈と活用法　Ⅹ.QOL．東京，メジカルビュー社；2019：235-250．
  • Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan KHX, Hammer-Helmich L, Fernandez J. Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J. J Affect Disord. 2019 Nov 1; 258:172-178.
  • Mugii N, Someya F, Noto S, Hamaguchi Y, Matsushita T, Takehara K. Availability of EuroQol-5-Dimensions-5-Level (EQ-5D-5L) as health-related QOL assessment for Japanese systemic sclerosis patients. Mod Rheumatol. 2019 Jul 22:1-6.
  • Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Hino A, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Noto S, Shimozuma K. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. Qual Life Res. 2019 Sep;28(9):2383-2391.
  • Noto S, Shiroiwa T, Kobayashi M, Murata T, Ikeda S, Fukuda T. Development of a multiplicative multi-attribute and single-attribute utility function for the HUI3 in Japan.  ISPOR Europe (Denmark, Copenhagen) 2019.11.2-6
  • Hashimoto M, Aogaki K, Numata C, Moriwaki K, Matsuda Y, Ishii R, Tanaka I, Okamoto Y. Factors influencing the prescribed dose of opioid analgesics in cancer patients. Journal of Opioid Management. 2019 (In press)
  • Inoue H, Uchiyama H, Moriwaki K, Yanagisawa S, Nishimura K. B. I. T. -Development of a dynamic visualization tool for Bayesian inference on various types of normal distributions for medical decision-making and education-. Niigata Journal of Health and Welfare 19(1) 24-36.2019
  • Saito S. Evaluating the effectiveness of a novel screening method for gastric cancer – the ABC method. 2019; Impact. 6:18-19.
  • Saito S, Nakazawa K, Nagahashi M, Ishikawa T, Akazawa K. Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. Per. Med. 2019; 16(6):439-448.
  • Nakazawa K, Saito S, Nagahashi M, Yamada A, Toyama A, Akazawa K. Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study. Health. 2019, 11(8):1017-1027.
  • Sano T, Izumi R, Ogawa M, Noto S. Influence of shoulder joint function and postoperative subjective symptoms on health-related QOL of breast cancer patients. Asian Journal of Occupational Therapy 15(1): 1-10, 2019.

2018年

  • 森脇健介. 骨粗鬆症治療における地域医療連携  骨粗鬆症治療介入による医療費削減効果. Progress in Medicine 38(1) 89‐94-94 2018
  • 佐野哲也、泉 良太、小川元大、能登真一．乳がん術後患者の健康関連QOL関連因子の解明－肩関節可動域と術後自覚症状の影響について－．作業療法 2018；37(3)：276-284．
  • 泉良太、佐野哲也．脳卒中患者の病型・損傷半球の違いによる健康関連QOLの差異－回復期リハビリテーション病棟における調査－．QOL J 2018；19(1)：34-43．
  • 齋藤翔太．胃がん検診の費用対効果分析手法．日本胃がん予知・診断・治療研究機構 Gastro-Health Now．2018年12月号
  • 齋藤翔太．バイオシミラーの医療経済．医薬ジャーナル．2019年3月号
  • Prayongrat A, Umegaki K, van der Schaaf A, Koong AC, Lin SH, Whitaker T, McNutt T, Matsufuji N, Graves E, Mizuta M, Ogawa K, Date H, Moriwaki K, Ito YM, Kobashi K, Dekura Y, Shimizu S, Shirato H. Present developments in reaching an international consensus for a model-based approach to particle beam therapy. Journal of radiation research 59(suppl_1) i72-i76 2018
  • Sengoku A, Noto S, Nomi M, Emmanuel A, Murata T, Mimura T. Cost-Effectiveness Analysis of Transanal Irrigation for Managing Neurogenic Bowel Dysfunction in Japan. JHEOR. 2018; 6: 37-52.
  • Saito S, Azumi M, Muneoka Y, Nishino K, Ishikawa T, Sato Y, Terai S, Akazawa K. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ. 2018, 19(4):545-555.
  • Saito S, Nakazawa K, Suzuki K, Ishikawa T, Akazawa K. Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan. Gastrointest Disord. 2018, 1(1):120-128.
  • Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Okamoto S. Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J): Protocol for a Prospective Cohort Study. JMIR Res Protoc. 2018 Jun 25;7(6):e161.
  • Uechi S, Moriwaki K. Preliminary Analysis Of The Cost-Effectiveness Of Pertuzmab In Patients With Her2-Positive Breast Cancer In Japan. Value in Health 21 S15 2018
  • Hagino Y, Moriwaki K. Development Of An Economic Model To Assess The Cost-Effectiveness Of Proton Beam Therapy In Patients With Hepatocellular Carcinoma In Japan. Value in Health 21 S15 2018
  • Fujiwara T, Moriwaki K. Estimation Of Cost Parameters Using Claims Database For Use In Cost-Effectiveness Analysis Of Lung Cancer Treatment In Japan. Value in Health 21 S12 2018
  • Murasawa H, Okabe T, Wakumoto Y, Sugiyama T, Tanaka N, Matsuoka Y, Noto S, Shimozuma K. Health-related quality of life in Japanese patients with prostate cancer using EQ-5D-5L and FACT-P: Comparisons according to treatment type. Value in Health 21 S17 2018
  • Noto S, Fukuda T, Saito S, Shimozuma K, Ikeda S, Shiroiwa T, Igarashi A, Ishida H, Moriwaki K, Kobayashi M. Preference-Based Health-Related Quality Of Life For Heart Disease Patients In Japan. Value in Health 21 S31 2018
  • Sano T, Izumi R, Ogawa M, Noto S. Clarification of health-related QOL related factors for breast cancer patients - Influence on the range of shoulder joint movement and postoperative subjective symptom -. International society of quality of life research 25th annual conference. Dublin, Ireland. 2018.10.24-27.
  • Izumi R, Sano T, Takizawa H, Yamamoto Y, Hori A, Wada A, Iguchi E, Suzukamo Y, Noto S. Investigation of the minimally important difference of HRQOL in stroke patients on recovery-phase rehabilitation wards -Using anchor-based and distribution-based methods. International society of quality of life research 25th annual conference. Dublin, Ireland. 2018.10.24-27.
  • Saito S, Nakazawa K, Nagahashi M, Akazawa K. COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPAN. ISPOR Europe 2018. Barcelona, Spain. 2018.11.10-14.

2017年

  • 森脇健介. 骨粗鬆症リエゾンサービスの費用対効果. Clinical Calcium 27(9) 1295‐1301 2017
  • 森脇健介. 骨粗鬆症のQOL・ADL評価. THE BONE 31(1) 97‐100 2017
  • 森脇健介. 骨折リエゾンサービスの医療費節減効果. Osteoporosis Japan Plus 2(1) 34‐37 2017
  • 森脇健介. 骨粗鬆症診療における多職種連携と医療経済評価―骨折リエゾンサービスの費用効果分析―. 日本骨粗鬆症学会雑誌 3(1) 111‐112 2017
  • 森脇健介. 免疫チェックポイント阻害薬の医療経済. ファルマシア 53(10) 976‐978 2017
  • 泉良太、佐野哲也．脳血管障害患者におけるEQ-5D-3LとEQ-5D-5Lの差異．QOL J 2017；18(1)：36-43．
  • Moriwaki K, Fukuda H. Cost-Effectiveness of Implementing Guidelines for the Treatment of Glucocorticoid-Induced Osteoporosis in Japan. 32nd Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, USA  2017
  • Moriwaki K, Noto S. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan. Osteoporos Int. 2017; 28: 621-632.
  • Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017;28: 643-652.
  • Nagayama H, Tomori K, Ohno K, Takahashi K, Nagatani R, Izumi R, Moriwaki K, Yamauchi K. Cost effectiveness of the occupation based approach for subacute stroke patients: Result of a randomized controlled trial. Topics in Stroke Rehabilitation 2017; 1-8.
  • Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis International 2017; in press.

2016年

  • 森脇健介. 骨粗鬆症の医療経済．骨粗鬆症治療薬クリニカルクエスチョン100．診断と治療社．pp167-168. 2016．
  • 森脇健介. 医療経済からみた骨粗鬆症治療．medicina 53(3)430-433. 2016．
  • 森脇健介. 骨折予防介入の費用対効果. 日本整形外科学会雑誌 90: 205-210. 2016．
  • 泉良太、佐野哲也．脳血管障害患者のEQ-5D-5L視覚評価法に影響を及ぼす因子の解明～回復期リハビリテーション病棟における調査～．QOL J 2016；17(1)：56-64．
  • Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value Health. 2016; 19: 648-54.
  • Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016; 25: 707-19.
  • Fukuda H, Moriwaki K. Cost-effectiveness analysis of safety-engineered devices. Infection Control & Hospital Epidemiology 2016; in press.
  • Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value in Health 2016; in press.
  • Noto S, Izumi R, Moriwaki K, Shiroiwa T, Igarashi A, Fukuda T, Ikeda S, Saito S, Ishida H. Comparison Between Eq-5d And Hui In Japanese Population Norms. International Society for Pharmacoeconomics and Outcomes Research 19th Annual European Meeting (Vienna, Austria), 2016.11.4～11.6.
  • Saito S, Noto S, Miyazaki M．Health Utility Measured with EQ-5D-5L in Japanese Patients Undergoing Hemodialysis. ISPOR 7th Asia-Pacific Conference, (Singapore), 2016.9.3～9.6．
  • Fukuda T, Igarashi A, Ishida H, Ikeda S, Saito S, Sakamaki H, Shimozuma K, Shiroiwa T, Takura T, Tomita N, Noto S, Fukuda H, Moriwaki K, Moriyama Y, Akazawa M. Economic Evaluation Guideline for Pharmaceuticals and Medical Devices in Japan. ISPOR 7th Asia-Pacific Conference, (Singapore), 2016.9.3～9.6.
  • Igarashi A, Fukuda T, Kobayashi M, Noto S, Saito S, Shimozuma K, Shiroiwa T, Ikeda S. Application of EQ-5D-5L / EQ-5D-3L to the general public –survey for population norm-. 33rd EuroQol Group Scientific Plenaly, (Berlin, Germany), 2016.9.15~9.16.

2015年

  • 森脇健介．医療経済評価の視点から見る今後の骨・関節疾患．骨・関節・軟骨治療のための新製品開発と臨床ニーズ．情報技術協会．2015．pp3-12．
  • 森脇健介（分担）．骨粗鬆症の予防と治療ガイドライン2015年版．骨粗鬆症の予防と治療ガイドライン編集委員会．2015．
  • 森脇健介．骨粗鬆症治療と医療経済評価．最新医学別冊　診断と治療のABC110．骨粗鬆症2015：197-198．2015.
  • 森脇健介．骨粗鬆症の薬物治療と費用対効果の検討．日本臨床2015；73（10）：1754-1759．2015.
  • Hirase S, Hasegawa D, Takahashi H, Moriwaki K, Saito A, et al. Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia. Int J Hematol. 2015; 102(5): 594-601.
  • Shiroiwa T, Saito S, Shimozuma K, Kodama S, Noto S, Fukuda T. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making. Appl Health Econ Health Policy. 2016;14: 375-85.
  • Moriwaki K, Noto S. Validation of fracture risk model in Japanese women compared with FRAX. PRM89. ISPOR 18th Annual European Congress. Milan, Italy. 2015.11.7-11.
  • Noto S, Izumi R, Shiroiwa T, Igarashi A, Ikeda S, Fukuda T, Saito S, Shimozuma K, Kobayashi M, Moriwaki K, Ishida H. Comparison Between The Interim Eq-5d-5l Score And The New Japanese Scoring In Stroke Patients. International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Meeting. Milan, Italy. 2015.11.7-11.

2014年

  • 能登真一．医療経済評価における効用値評価－EQ-5D，HUIを中心に－．(財)レギュラトリーサイエンス財団編．基礎から学ぶ医療経済評価．じほう，東京．2014．pp165-179．
  • 能登真一，村井千賀，竹内さをり，岩瀬義昭，中村春基．地域在住の要介護高齢者に対する「生活行為向上マネジメント」を用いた作業療法の効果　多施設共同ランダム化比較試験．作業療法 2014；33：259-269．
  • 池田俊也，白岩健，五十嵐中，能登真一，福田敬，齋藤信也，下妻晃二郎．日本語版EQ-5D-5Lにおけるスコアリング法の開発．保健医療科学 2014；64：47-55．
  • 森脇健介．骨粗鬆症・骨折の医療経済．Clin Calcium 2014；24(5)：711-718．
  • 森脇健介．骨量減少症日本人女性に対する骨折予防治療の費用対効果．O.li.v.e.―骨代謝と生活習慣病の連関― 2014；4(2)：90-94．
  • Izumi R, Noto S, Ikeda S, Fukuda T, Shiroiwa T, Igarashi A. Comparison of three utility measures in stroke patients using item response theory analysis. Niigata Journal of Health and Welfare, 2014; 13 (1): 1-12.
  • 泉良太．健康関連QOLに影響を及ぼすADL因子の検討．QOL J 2014；15(1)：11-17．
  • 泉良太，能登真一．項目反応理論分析を用いた脳血管障害患者におけるHealth Utilities Index Mark 3の測定特性の検討．医療経済研究 2014；25(2)：126-138．
  • Noto S, Murai C, Takeuchi S, Iwase Y, Nakamura H. Long-term effect of using "the management tool for daily life performance”. 16th International Congress of the World Federation of Occupational Therapists. Yokohama, Japan. 2014.6.18-21.
  • Noto S, Shimozuma K, Saito S, Shiroiwa T, Fukuda T, Moriwaki K, Izumi R. A Comparison of Value for Health States Worse Than Dead Between Japan and UK. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Noto S, Izumi R, Moriwaki K. Long-Term Grading of Health-Related Quality of Life of Care-Needed Elderly: A 2-Yr Follow-Up Study. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Moriwaki K, Yoshimura M, Izumi R, Noto S. Cost-Effectiveness of Multiple Anti-Osteoporotic Therapies for Secondary Fracture Prevention in Japan. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Yoshimura M, Moriwaki K, Noto S, Takiguchi T. Health Economic Evaluation of Osteoporosis Screening and Treatment Strategy in the Elderly Japanese Women. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Izumi R, Noto S, Uemura T. Difference of the health-related quality of life according to a diagnosis of the stroke in recovery phase. 16th International Congress of the World Federation of Occupational Therapists. Yokohama, Japan. 2014.6.18-21.

2013年

  • 能登真一．医療経済からみたリハビリテーションの成果と効果．専門リハ 2013；12：2-6．
  • 能登真一．生活行為向上マネジメントと経済的効果に関する検証．日本作業療法士協会誌 2013；17：28-29．
  • 福田敬, 白岩健, 池田俊也, 五十嵐中, 赤沢学, 石田博, 能登真一, 齋藤信也, 坂巻弘之, 下妻晃二郎, 田倉智之, 福田治久, 森脇健介, 冨田奈穂子, 小林慎．医療経済評価研究における分析手法に関するガイドライン．保健医療科学 2013；62：625-640．
  • Izumi R, Noto S, Uemura T, Ikeda S, Fukuda T. Comparison of three utility measures using item response theory analysis in stroke patients. International society of quality of life research 20th annual conference. Miami, FL, USA. 2013.10.9-12.

2012年

  • Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. Journal of Bone and Mineral Research. 2012; 28(2):395-403. Impact Factor: 6.373 in 2011
  • Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I, Fukagawa M. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 2012;60(2):262–271. ＜H.K. and K.M. contributed equally to this work＞ Impact Factor: 5.434 in 2011
  • Moriwaki K, Noto S. Dynamic simulation analysis for optimal sickbed allocation in a hospital. Journal of Niigata Health and Welfare. 2012;11(1):1-11.
  • Matsuzawa T, Takata T, Yokono K, Ueda H, Moriwaki K, Kamae I, Urakami K, Sakurai T. A warning index used in prescreening for Alzheimer’s disease, based on self-reported cognitive deficits and vascular risk Factors for dementia in elderly patients with type 2 diabetes. International Journal of Alzheimer's Disease. 2012; Article ID 124215, 8 pages
  • 福田敬, 白岩健, 五十嵐中, 小林慎, 池田俊也, 能登真一, 下妻晃二郎, 坂巻弘之．世界で医療経済評価はどのように用いられているか?　7ヶ国の比較調査結果と日本での応用可能性についての検討．医療経済研究 2012；23：147-164．
  • 齋藤信也, 児玉聡, 白岩健, 下妻晃二郎, 能登真一, 後藤玲子．医療資源配分とQALYに関する倫理的側面からの考察．薬剤疫学 2012；17：47-53．
  • 泉良太，能登真一，上村隆元．脳疾患患者における健康関連QOL尺度の検討　項目反応理論による識別力・難易度の推定．QOL J 2012；13(1)：93-102．
  • Noto S, Uemura T, Moriwaki K. Change in health-related quality of life after occupational therapy in community-dwelling dependent elderly: a randomized controlled trial. International society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Berlin, Germany. 2012.11.5-8.
  • Noto S, Izumi R, Moriwaki K, Igarashi A, Ikeda S, Fukuda T, Shiroiwa T, Kobayashi M, Saito S, Shimozuma K. Comparing the performance of the EQ-5D-5L with the EQ-5D-3L in stroke patients in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Toujo T, Inoue H, Fukagawa M, Takahashi HE. Cost-effectiveness analysis of alendronate therapy for secondary prevention of osteoporotic fractures. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Moriwaki K, Ito S, Kobayashi D, Noto S, Yanagisawa S, Toujou T, Murasawa A . Predicting EQ-5D utility scores from SF-36 scores in patinets with rheumatoid arthritis in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Fukuda T, Akazawa M, Fukuda H, Igarashi A, Ikeda S, Ishida H, Kobayashi M, Moriwaki K, Noto S, Sakamaki H, Saito S, Shimozuma K, Shiroiwa T, Takura T, Tomita N. Proposal of economic evaluation guideline in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.

2011年

  • 森脇健介（分担翻訳）；臨床経済学研究会・ISPOR 日本部会, ISPOR 用語集翻訳委員会. ヘルスケアサイエンスのための医薬経済学用語集．東京：医薬出版センター；2011．

Ÿ   Noto S, Miyazaki M, Takeuchi H, Saito S. Relationship between hemodialysis and health-related quality of life: a cross-sectional study of diagnosis and duration of hemodialysis. Renal Replacement Therapy. 2021; 7, Article number: 62.

Ÿ   Obata H, Izumi T, Yamashita M, Mitsuma W, Suzuki K, Noto S, Morimoto T, Isobe M. Characteristics of Elderly Patients with Heart Failure and Impact on Activities of Daily Living: A Registry Report from Super-Aged Society. J Card Fail. 2021 Nov;27(11):1203-1213.

Ÿ   Iwatani T, Noto S, Tsugawa K. Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer. Curr Oncol. 2021 Oct 18;28(5):4203-4212.

Ÿ   Noto S, Saito S, Shiroiwa T, Fukuda T. Estimation of Lifetime QALYs Based on Lifestyle Behaviors. Int J Environ Res Public Health. 2021 Sep 22;18(19):9970.

Ÿ   Shiroiwa T, Noto S, Fukuda T. Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings. Value Health. 2021 Aug;24(8):1193-1202.

Ÿ   Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021 Jul;41(5):597-606.

Ÿ   Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J. Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J. Neuropsychiatr Dis Treat. 2021 Mar 26;17:945-955.

Ÿ   Saito S, Qi R, Tran HTT, Suzuki K, Takiguchi T, Noto S, Ohde S, Takahashi O. A nationwide web-based survey of factors associated with depressive symptoms among Japanese workers. Int J Soc Psychiatry. 2021 May 13:207640211017586.

Ÿ   Saito S, Tran HTT, Qi R, Suzuki K, Takiguchi T, Ishigami K, Noto S, Ohde S, Takahashi O. Psychological impact of the state of emergency over COVID-19 for non-permanent workers: a Nationwide follow-up study in Japan. BMC Public Health. 2021 Feb 11;21(1):334.

Ÿ   Ishihara K, Izawa KP, Noto S, Shimizu I. Physical and Mental Functions of Cardiovascular Diseased Patients Decrease During the State of Emergency Initiated by the COVID-19 Pandemic in Japan. Rev Recent Clin Trials. 2021;16(3):316-321.

Ÿ   Morimoto K, Moriwaki K, Kaneyasu T, Nakayama H, Shimozuma K. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan. Value Health Reg Issues. 2022 Mar;28:54-60. doi: 10.1016/j.vhri.2021.04.003. Epub 2021 Nov 17. PMID: 34800832.

Ÿ   Mizumoto M, Fuji H, Miyachi M, Soejima T, Yamamoto T, Aibe N, Demizu Y, Iwata H, Hashimoto T, Motegi A, Kawamura A, Terashima K, Fukushima T, Nakao T, Takada A, Sumi M, Oshima J, Moriwaki K, Nozaki M, Ishida Y, Kosaka Y, Ae K, Hosono A, Harada H, Ogo E, Akimoto T, Saito T, Fukushima H, Suzuki R, Takahashi M, Matsuo T, Matsumura A, Masaki H, Hosoi H, Shigematsu N, Sakurai H. Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines. Cancer Treat Rev. 2021 Jul;98:102209. doi: 10.1016/j.ctrv.2021.102209. Epub 2021 Apr 16. PMID: 33984606.

Ÿ   Ohde S, Moriwaki K, Takahashi O. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification. BMC Endocr Disord. 2021 May 22;21(1):105. doi: 10.1186/s12902-021-00771-0. PMID: 34022872; PMCID: PMC8141129.

Ÿ   泉　良太，能登真一，佐野哲也，鈴木達也．回復期リハビリテーション病棟における健康関連QOLの変化と代理人回答の一致度について-脳卒中患者へのEQ-5D-5Lによる評価-．日本臨床作業療法研究2021；8：31-36．